February 2018- Volume 14, Issue 2

In this Issue

Commentary

Guest Commentary: Turning text into insights

Guest Commentary: Turning text into insights

There is too much published research for a person to keep up with; fortunately, with the right technology, such as text mining tools, researchers can overcome this challenge

Catching the wave in 2018

Catching the wave in 2018

Peter Kissinger takes some time to answer a few questions from readers of his column

Contract Services

What’s in a name?

What’s in a name?

Two contract services providers change their monikers as part of strategic shifts

Room to grow

Room to grow

Rho builds new headquarters to meet needs of growing contract research operations

A new COO and a bigger footprint

A new COO and a bigger footprint

Cromos looks to establish a more global presence

Clinical Trials

Two big hits for Agios

Two big hits for Agios

Presentations showcase company’s development in cancer treatment

Beating back the bipolar blues

Beating back the bipolar blues

Primary endpoint met in study of patients treated with cariprazine for acute bipolar I depression

Hunter syndrome slips Shire’s net

Hunter syndrome slips Shire’s net

Shire announces disappointing top-line results for SHP609 trial in children with Hunter syndrome and cognitive impairment

A second candidate against MDR infections

A second candidate against MDR infections

Achaogen boasts positive top-line results from first clinical trial of oral antibacterial C-Scape

Discovery

Crohn’s and Parkinson’s in cahoots?

Crohn’s and Parkinson’s in cahoots?

Gene mutations found in Crohn’s patients suggest possible link with Parkinson’s disease

The new ‘IT’ thing in drug discovery

The new ‘IT’ thing in drug discovery

Global pharma drug discovery IT solutions to reach $5.3B by 2020, says Frost & Sullivan

Muscling up on stem cells

Muscling up on stem cells

Researchers track muscle stem cell dynamics in response to injury and aging

A new way to treat diabetes

A new way to treat diabetes

Follicum identifies receptors in insulin-producing cells for potential new class of diabetes drugs

Microbial mysteries

Microbial mysteries

TSRI unlocks secrets of deadly virus and finds clues to cancer treatment in bacteria

Diagnostics

Breast cancer biomarkers

Breast cancer biomarkers

Immune checkpoint blockade therapy could be promising

East meets West for MoU

East meets West for MoU

BGI, Hummingbird Diagnostics join hands for early diagnosis of Alzheimer’s and Parkinson's diseases

Illumina partners with KingMed

Illumina partners with KingMed

Companies aim to develop NGS technology for Chinese FDA approval

Diagnostic technology goes 3D

Diagnostic technology goes 3D

New research study demonstrates applicability of VisionGate’s Cell-CT platform

Preclinical

Pioneering solid-tumor cancer program

Pioneering solid-tumor cancer program

NANOBIOTIX partners with Providence Cancer Institute for immunotherapeutic preclinical research

New subsidiary, new AAV gene therapies

New subsidiary, new AAV gene therapies

The most promising novel treatment, Tamid-001, may stop hereditary ocular disease

Test-driving a potential autism drug

Test-driving a potential autism drug

Research shows drug candidate NitroSynapsin helps correct signaling imbalances in animal models

Saniona selects preclinical candidate

Saniona selects preclinical candidate

New potential therapy resides in GABAA α2/α3 program for neuropathic pain and chronic itching

Business & Government Policy

Celgene to acquire Juno for $9 billion

Celgene to acquire Juno for $9 billion

Acquisition will add novel scientific platform and manufacturing expertise to Celgene’s research and operational capabilities

Generation Bio launches into genetic medicine

Generation Bio launches into genetic medicine

Startup aims to develop truly drug-like genetic medicines based on its GeneWave technology

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Vical restructures to focus on HSV-2 and antifungal programs

Vical restructures to focus on HSV-2 and antifungal programs

Company expects to report that it ended 2017 with cash and investments of approximately $60M to $65M

Patent Docs: Supreme Court expansion of patent-limiting doctrine puts branded drugs at risk

Patent Docs: Supreme Court expansion of patent-limiting doctrine puts branded drugs at risk

The significance of the legal decision to pharmaceutical products and the patents that protect their exclusivity arises from the aspect of the decision relating to exhaustion cause by foreign sales

Research & Development

Potentially powerful cancer biomarker identified

Potentially powerful cancer biomarker identified

Protein expression may predict risk of colorectal cancer recurrence

Making the ‘best’ better

Making the ‘best’ better

Media system extends lifespan of functional neurons to advance neurodegenerative research

MVA-VLP platform is ‘MVP’ in new collaboration

MVA-VLP platform is ‘MVP’ in new collaboration

GeoVax, Vaxeal will apply GeoVax’s MVA-VLP platform to generate cancer vaccines

Agilent collaborates with USC

Agilent collaborates with USC

Team-up aims to facilitate transformational biomedical science and engineering research

A meeting of metabolomics

A meeting of metabolomics

Biocrates Life Sciences acquires Metanomics Health

Special Reports

Editor's Focus

Editor’s focus: Whose business is it, anyway?

Editor’s focus: Whose business is it, anyway?

In the healthcare realm, outside forces with money, resources and will are moving in to take charge of costs and efficiencies. The question is, will they really be able to make a difference, and how long before we see similar activity in pharma and biotech?
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2021 Issue Front Cover

Latest Issue  

• Volume 17 • Issue 11 • November 2021

November 2021

November 2021 Issue